Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study.
Wen ZhangXiaohong HanLin YangYuanyuan SongLiangzhi XieWenlin GaiYan WangYuan-Kai ShiPublished in: BMC cancer (2022)
This study was registered with ClinicalTrials.gov ( NCT02211443 ).